170 related articles for article (PubMed ID: 28394704)
1. Analysis of novel meningococcal vaccine formulations.
Zughaier SM
Hum Vaccin Immunother; 2017 Jul; 13(7):1728-1732. PubMed ID: 28394704
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of various adjuvant nanoparticulate formulations for meningococcal capsular polysaccharide-based vaccine.
Gala RP; D'Souza M; Zughaier SM
Vaccine; 2016 Jun; 34(28):3260-7. PubMed ID: 27177946
[TBL] [Abstract][Full Text] [Related]
3. A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial.
Block SL; Szenborn L; Daly W; Jackowska T; D'Agostino D; Han L; Dull PM; Smolenov I
Vaccine; 2015 May; 33(21):2500-10. PubMed ID: 25795256
[TBL] [Abstract][Full Text] [Related]
4. Induction of death receptor CD95 and co-stimulatory molecules CD80 and CD86 by meningococcal capsular polysaccharide-loaded vaccine nanoparticles.
Ubale RV; Gala RP; Zughaier SM; D'Souza MJ
AAPS J; 2014 Sep; 16(5):986-93. PubMed ID: 24981893
[TBL] [Abstract][Full Text] [Related]
5. Fighting Neisseria meningitidis: past and current vaccination strategies.
Piccini G; Torelli A; Gianchecchi E; Piccirella S; Montomoli E
Expert Rev Vaccines; 2016 Nov; 15(11):1393-1407. PubMed ID: 27158988
[TBL] [Abstract][Full Text] [Related]
6. A randomized trial to assess safety and immunogenicity of alternative formulations of a quadrivalent meningococcal (A, C, Y, and W-135) tetanus protein conjugate vaccine in toddlers.
McVernon J; Nolan T; Richmond P; Reynolds G; Nissen M; Lambert SB; Marshall H; Papa T; Rehm C
Pediatr Infect Dis J; 2012 Jan; 31(1):e15-23. PubMed ID: 22094636
[TBL] [Abstract][Full Text] [Related]
7. Preclinical immunogenicity and functional activity studies of an A+W meningococcal outer membrane vesicle (OMV) vaccine and comparisons with existing meningococcal conjugate- and polysaccharide vaccines.
Tunheim G; Arnemo M; Næss LM; Fjeldheim ÅK; Nome L; Bolstad K; Aase A; Mandiarote A; González H; González D; García L; Cardoso D; Norheim G; Rosenqvist E
Vaccine; 2013 Dec; 31(51):6097-106. PubMed ID: 24120679
[TBL] [Abstract][Full Text] [Related]
8. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
9. Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB--potential for broad protection against meningococcal disease.
Dull PM; McIntosh ED
Vaccine; 2012 May; 30 Suppl 2():B18-25. PubMed ID: 22607895
[TBL] [Abstract][Full Text] [Related]
10. Low immunogenicity of quadrivalent meningococcal vaccines in solid organ transplant recipients.
Wyplosz B; Derradji O; Hong E; François H; Durrbach A; Duclos-Vallée JC; Samuel D; Escaut L; Launay O; Vittecoq D; Taha MK
Transpl Infect Dis; 2015 Apr; 17(2):322-7. PubMed ID: 25645691
[TBL] [Abstract][Full Text] [Related]
11. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
Papaevangelou V; Spyridis N
Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
[TBL] [Abstract][Full Text] [Related]
12. Primary and booster mucosal immune responses to meningococcal group A and C conjugate and polysaccharide vaccines administered to university students in the United Kingdom.
Zhang Q; Lakshman R; Burkinshaw R; Choo S; Everard J; Akhtar S; Finn A
Infect Immun; 2001 Jul; 69(7):4337-41. PubMed ID: 11401971
[TBL] [Abstract][Full Text] [Related]
13. Does post-implementation vaccine effectiveness data support pre-implementation predictions of 4CMenB utility?
Findlow J; Borrow R
Pathog Dis; 2017 Mar; 75(2):. PubMed ID: 28334397
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines.
Sanders H; Feavers IM
Expert Rev Vaccines; 2011 Mar; 10(3):323-34. PubMed ID: 21434800
[TBL] [Abstract][Full Text] [Related]
15. Meningococcal B vaccine. An immunogenic vaccine possibly useful during outbreaks.
Prescrire Int; 2014 Sep; 23(152):201-4. PubMed ID: 25325113
[TBL] [Abstract][Full Text] [Related]
16. Formulation of meningococcal capsular polysaccharide vaccine-loaded microparticles with robust innate immune recognition.
Ubale RV; D'Souza MJ; Infield DT; McCarty NA; Zughaier SM
J Microencapsul; 2013; 30(1):28-41. PubMed ID: 22657751
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
[TBL] [Abstract][Full Text] [Related]
18. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
Pace D
Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of a tetravalent polysaccharide vaccine against meningococcal disease.
Shao PL; Chang LY; Hsieh SM; Chang SC; Pan SC; Lu CY; Hsieh YC; Lee CY; Dobbelaere K; Boutriau D; Tang H; Bock HL; Huang LM
J Formos Med Assoc; 2009 Jul; 108(7):539-47. PubMed ID: 19586827
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants.
Perrett KP; Snape MD; Ford KJ; John TM; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
Pediatr Infect Dis J; 2009 Mar; 28(3):186-93. PubMed ID: 19209097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
